Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses

• Published in: Journal of antimicrobial chemotherapy Vol. 79; no. 8; pp. 1985 - 1989
• Main Authors: Puça, Maria Carolina Silva De Barros, Rodrigues, Danielle Fonseca, Salazar, Yanka Evellyn Alves Rodrigues, Louzada, Jaime, Fontes, Cor Jesus Fernandes, Daher, André, Pereira, Dhélio Batista, Fernandes Vieira, José Luiz, Carvalho, Luzia Helena, Alves de Brito, Cristiana Ferreira, Gil, José Pedro, Nobrega de Sousa, Tais
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.08.2024
• Subjects: Adult; Antimalarials - therapeutic use; Cytochrome P-450 CYP2D6 - genetics; Cytochrome P-450 CYP2D6 - metabolism; Female; Genotype; Humans; Malaria, Vivax - drug therapy; Malaria, Vivax - genetics; Male; Middle Aged; Monoamine Oxidase - genetics; Original Research; Plasmodium vivax - genetics; Polymorphism, Genetic; Primaquine - therapeutic use; Recurrence; Retrospective Studies
• ISSN: 0305-7453; 1460-2091; 1460-2091
• DOI: 10.1093/jac/dkae196

Primaquine is essential for the radical cure of Plasmodium vivax malaria and must be metabolized into its bioactive metabolites. Accordingly, polymorphisms in primaquine-metabolizing enzymes can impact the treatment efficacy. This pioneering study explores the influence of monoamine oxidase-A (MAO-A) on primaquine metabolism and its impact on malaria relapses. Samples from 205 patients with P. vivax malaria were retrospectively analysed by genotyping polymorphisms in MAO-A and cytochrome P450 2D6 (CYP2D6) genes. We measured the primaquine and carboxyprimaquine blood levels in 100 subjects for whom blood samples were available on the third day of treatment. We also examined the relationship between the enzyme variants and P. vivax malaria relapses in a group of subjects with well-documented relapses. The median carboxyprimaquine level was significantly reduced in individuals carrying low-expression MAO-A alleles plus impaired CYP2D6. In addition, this group experienced significantly more P. vivax relapses. The low-expression MAO-A status was not associated with malaria relapses when CYP2D6 had normal activity. This suggests that the putative carboxyprimaquine contribution is irrelevant when the CYP2D6 pathway is fully active. We found evidence that the low-expression MAO-A variants can potentiate the negative impact of impaired CYP2D6 activity, resulting in lower levels of carboxyprimaquine metabolite and multiple relapses. The findings support the hypothesis that carboxyprimaquine may be further metabolized through CYP-mediated pathways generating bioactive metabolites that act against the parasite.